Monte Rosa Therapeutics Inc - Asset Resilience Ratio
Monte Rosa Therapeutics Inc (GLUE) has an Asset Resilience Ratio of 68.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Monte Rosa Therapeutics Inc's Asset Resilience Ratio has changed over time. Check how strategically is Monte Rosa Therapeutics Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Monte Rosa Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Monte Rosa Therapeutics Inc (GLUE) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $506.36 Million | 68.76% |
| Total Liquid Assets | $506.36 Million | 68.76% |
Asset Resilience Insights
- Very High Liquidity: Monte Rosa Therapeutics Inc maintains exceptional liquid asset reserves at 68.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Monte Rosa Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Monte Rosa Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Monte Rosa Therapeutics Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Monte Rosa Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 55.10% | $247.22 Million | $448.66 Million | +21.39pp |
| 2024-12-31 | 33.71% | $147.90 Million | $438.73 Million | -0.63pp |
| 2023-12-31 | 34.34% | $104.31 Million | $303.75 Million | -26.38pp |
| 2022-12-31 | 60.72% | $207.91 Million | $342.39 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $366.33 Million | -- |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more